Wall Street analysts expect Cypherpunk Technologies to report a loss of $0.03 per share on $0.00 in revenue for Q2 2026, as the stock trades at approximately $0.67 with an average price target of $0.90. The primary focus for investors is the valuation of the company's Zcash (ZEC) treasury holdings, which has historically caused significant swings in reported net income due to unrealized gains and losses. Since its strategic rebranding, the firm has aggressively accumulated ZEC, holding over 320,000 units by mid-2026 while simultaneously managing a clinical-stage biopharmaceutical pipeline. Markets are particularly attentive to whether the dual strategy of privacy-tech investment and oncology drug development can reduce the company's trailing net losses.